Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/REL_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/REL_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/REL_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/REL_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/REL_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/REL_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/REL_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/REL_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:190332119 | Prostate | Tumor | negative regulation of protein modification by small protein conjugation or removal | 38/3246 | 95/18723 | 1.49e-07 | 3.76e-06 | 38 |
GO:190370617 | Prostate | Tumor | regulation of hemopoiesis | 103/3246 | 367/18723 | 1.78e-07 | 4.38e-06 | 103 |
GO:004343418 | Prostate | Tumor | response to peptide hormone | 113/3246 | 414/18723 | 2.24e-07 | 5.42e-06 | 113 |
GO:006161416 | Prostate | Tumor | pri-miRNA transcription by RNA polymerase II | 26/3246 | 55/18723 | 2.84e-07 | 6.53e-06 | 26 |
GO:004362019 | Prostate | Tumor | regulation of DNA-templated transcription in response to stress | 25/3246 | 53/18723 | 5.06e-07 | 1.09e-05 | 25 |
GO:001095018 | Prostate | Tumor | positive regulation of endopeptidase activity | 58/3246 | 179/18723 | 6.35e-07 | 1.32e-05 | 58 |
GO:000961514 | Prostate | Tumor | response to virus | 101/3246 | 367/18723 | 6.40e-07 | 1.32e-05 | 101 |
GO:190289316 | Prostate | Tumor | regulation of pri-miRNA transcription by RNA polymerase II | 25/3246 | 54/18723 | 7.88e-07 | 1.56e-05 | 25 |
GO:007137514 | Prostate | Tumor | cellular response to peptide hormone stimulus | 83/3246 | 290/18723 | 1.14e-06 | 2.16e-05 | 83 |
GO:003286915 | Prostate | Tumor | cellular response to insulin stimulus | 63/3246 | 203/18723 | 1.15e-06 | 2.18e-05 | 63 |
GO:007099719 | Prostate | Tumor | neuron death | 98/3246 | 361/18723 | 1.81e-06 | 3.19e-05 | 98 |
GO:200123719 | Prostate | Tumor | negative regulation of extrinsic apoptotic signaling pathway | 36/3246 | 97/18723 | 2.61e-06 | 4.38e-05 | 36 |
GO:000854415 | Prostate | Tumor | epidermis development | 89/3246 | 324/18723 | 3.15e-06 | 5.18e-05 | 89 |
GO:006100817 | Prostate | Tumor | hepaticobiliary system development | 49/3246 | 150/18723 | 3.52e-06 | 5.70e-05 | 49 |
GO:003461418 | Prostate | Tumor | cellular response to reactive oxygen species | 50/3246 | 155/18723 | 4.22e-06 | 6.67e-05 | 50 |
GO:000188917 | Prostate | Tumor | liver development | 48/3246 | 147/18723 | 4.47e-06 | 7.02e-05 | 48 |
GO:003286815 | Prostate | Tumor | response to insulin | 75/3246 | 264/18723 | 4.94e-06 | 7.68e-05 | 75 |
GO:190289515 | Prostate | Tumor | positive regulation of pri-miRNA transcription by RNA polymerase II | 20/3246 | 42/18723 | 5.80e-06 | 8.86e-05 | 20 |
GO:001820512 | Prostate | Tumor | peptidyl-lysine modification | 99/3246 | 376/18723 | 6.77e-06 | 1.02e-04 | 99 |
GO:004358815 | Prostate | Tumor | skin development | 74/3246 | 263/18723 | 8.28e-06 | 1.22e-04 | 74 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
REL | SNV | Missense_Mutation | rs758702004 | c.392N>G | p.Asn131Ser | p.N131S | Q04864 | protein_coding | tolerated(0.14) | benign(0.012) | TCGA-A7-A3IZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
REL | SNV | Missense_Mutation | novel | c.279T>G | p.Phe93Leu | p.F93L | Q04864 | protein_coding | tolerated(0.46) | probably_damaging(0.92) | TCGA-A7-A4SD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
REL | SNV | Missense_Mutation | | c.1066N>A | p.Glu356Lys | p.E356K | Q04864 | protein_coding | deleterious(0) | possibly_damaging(0.629) | TCGA-AN-A04C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
REL | insertion | Frame_Shift_Ins | novel | c.728_729insCACCAGATTAATC | p.Phe244ThrfsTer29 | p.F244Tfs*29 | Q04864 | protein_coding | | | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
REL | insertion | In_Frame_Ins | novel | c.1828_1829insGCCTACAGGGGTTTCAAGTCAAGCAGAATCCTACTATCCCTC | p.Asp610delinsGlyLeuGlnGlyPheGlnValLysGlnAsnProThrIleProHis | p.D610delinsGLQGFQVKQNPTIPH | Q04864 | protein_coding | | | TCGA-B6-A0IA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
REL | SNV | Missense_Mutation | novel | c.65G>A | p.Arg22His | p.R22H | Q04864 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
REL | SNV | Missense_Mutation | | c.469N>G | p.Pro157Ala | p.P157A | Q04864 | protein_coding | tolerated(0.11) | benign(0.127) | TCGA-C5-A1M8-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
REL | SNV | Missense_Mutation | | c.607N>A | p.Glu203Lys | p.E203K | Q04864 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-EK-A2PL-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
REL | SNV | Missense_Mutation | | c.946N>A | p.Asp316Asn | p.D316N | Q04864 | protein_coding | tolerated_low_confidence(0.61) | benign(0) | TCGA-JW-A852-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
REL | SNV | Missense_Mutation | | c.1722N>A | p.Met574Ile | p.M574I | Q04864 | protein_coding | tolerated_low_confidence(0.12) | benign(0) | TCGA-LP-A4AV-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |